Decoy Therapeutics Regains Nasdaq Listing Compliance, Averting Delisting
DCOY is trading near its 52-week low of $5.94 (4.0% above the low) on light trading volume (0.1× avg).
Summary
Decoy Therapeutics Inc. announced it has successfully regained compliance with Nasdaq's minimum bid price requirement, resolving a prior delisting threat and ensuring continued listing on The Nasdaq Capital Market.
Key Events · Corporate Governance and Compliance · DCOY
-
Nasdaq Compliance Regained
On March 31, 2026, the Nasdaq Hearings Panel confirmed that Decoy Therapeutics Inc. has regained compliance with the Minimum Bid Price Requirement and all other applicable listing requirements.
-
Delisting Threat Averted
This confirmation resolves the prior notice of non-compliance received on December 31, 2025, and averts a potential delisting from The Nasdaq Capital Market.
-
Reverse Stock Split Instrumental
The company implemented a reverse stock split, effective March 6, 2026, which was key to achieving the required bid price of at least $1.00 for 10 consecutive business days by March 20, 2026.
-
Mandatory Panel Monitor Imposed
Decoy Therapeutics will be subject to a Mandatory Panel Monitor until March 31, 2027, meaning any future non-compliance with the bid price requirement could lead to a delisting determination.
Analysis · DCOY · Life Sciences
Decoy Therapeutics Inc. has successfully regained compliance with Nasdaq's minimum bid price requirement, a critical development following a prior delisting notice and a recent 10-K filing that expressed substantial doubt about the company's ability to continue as a going concern. This resolution, achieved through a reverse stock split and sustained trading above the $1.00 threshold, removes an immediate existential threat to the company's public trading status. While the company will remain under a Mandatory Panel Monitor until March 31, 2027, this news provides a crucial lifeline, especially as the stock trades near its 52-week lows, indicating the company is actively addressing its operational challenges.
At the time of this filing, DCOY was trading at $6.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.4M. The 52-week trading range was $5.94 to $415.80. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.